Company / Accounts Receivable
10x Genomics, Inc. Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$47.0M
FY2025
5-year range
$47.0M / $114.8M
FY2021-FY2025
Trend
-46.5%
vs FY2024
Sector context
#117 of 143
Health Care
What the data says
10x Genomics, Inc.'s accounts receivable of $47M is lower than 82% of companies in the Health Care sector (FY2025). Declined from $115M to $47M over the past 2 years.
Based on SEC 10-K filings.
$47M in FY2025 with a 5-year CAGR of -1.7%.
Declined from $115M to $47M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -23.3%
- 5-Year CAGR
- -1.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 143This company $47.0M Sector average $1.3B
▼
-96.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.7%, indicating a declining trend.
- In FY2025, accounts receivable decreased 46.5% year-over-year.
- Ranks #117 out of 143 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.0M | -46.5% |
| FY2024 | $87.9M | -23.5% |
| FY2023 | $114.8M | +10.2% |
| FY2022 | $104.2M | +22.2% |
| FY2021 | $85.3M | +66.5% |
| FY2020 | $51.2M | +53.5% |
| FY2019 | $33.4M | +18.8% |
| FY2018 | $28.1M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026